Cardinal Health Is Investing Big in Nuclear & Theranostics — The Future of Precision Health!

Cardinal Health, Inc. (CAH) has shown a robust start to its fiscal year 2026, reflected in a solid financial performance for its first quarter. The company reported a 22% revenue increase to $64 billion, primarily fueled by strong demand in its Pharmaceutical and Specialty Solutions segment. This segment has seen a 23% revenue boost driven by brand and specialty pharmaceutical sales, as well as a 26% increase in segment profit. This growth is complemented by contributions from recent acquisitions, particularly Solaris Health, which is expected to significantly bolster Cardinal Health’s specialty growth strategy. On the operational front, the company has demonstrated disciplined execution, evident from its improved operating earnings by 37% and EPS growth of 36%. Such performance underscores Cardinal Health’s strategic focus on its core operations, delivering exceptional service and leveraging industry trends to drive business momentum.